汇宇制药:2024年报净利润3.25亿 同比增长132.14%

Financial Performance - The company reported a basic earnings per share of 0.7700 yuan for 2024, a 133.33% increase from 0.3300 yuan in 2023 [1] - Net profit for 2024 reached 3.25 billion yuan, up 132.14% from 1.4 billion yuan in 2023 [1] - Operating revenue increased to 10.94 billion yuan, an 18.02% rise compared to 9.27 billion yuan in the previous year [1] - The return on equity (ROE) improved to 8.43%, a significant increase of 124.8% from 3.75% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 12,745.42 million shares, accounting for 41.17% of the circulating shares, with a decrease of 17.45 million shares from the previous period [1] - Notable shareholders include Huang Qianyi with 2,721.94 million shares (8.79%), Wang Xiaopeng with 1,703.76 million shares (5.50%), and new entrant Hu Guoping with 1,527.33 million shares (4.93%) [2] - Several shareholders exited the top ten list, including Yang Bo, who held 2,115.99 million shares (7.27%) [2] Dividend Distribution - The company announced a dividend distribution of 4.632 yuan per share (including tax) [3]